Logo image of TESS

TESSCO Technologies Inc (TESS) Stock Fundamental Analysis

NASDAQ:TESS - US8723861071 - Common Stock

8.99 USD
+0.01 (+0.11%)
Last: 7/14/2023, 8:02:40 PM
8.99 USD
0 (0%)
After Hours: 7/14/2023, 8:02:40 PM
Fundamental Rating

2

Taking everything into account, TESS scores 2 out of 10 in our fundamental rating. TESS was compared to 48 industry peers in the Communications Equipment industry. TESS may be in some trouble as it scores bad on both profitability and health. TESS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TESS has reported negative net income.
In the past year TESS has reported a negative cash flow from operations.
TESS had negative earnings in 4 of the past 5 years.
In multiple years TESS reported negative operating cash flow during the last 5 years.
TESS Yearly Net Income VS EBIT VS OCF VS FCFTESS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

1.2 Ratios

TESS has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TESS Yearly ROA, ROE, ROICTESS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 -20

1.3 Margins

Looking at the Gross Margin, with a value of 20.16%, TESS is doing worse than 91.67% of the companies in the same industry.
TESS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for TESS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.85%
GM growth 5Y-0.55%
TESS Yearly Profit, Operating, Gross MarginsTESS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 10 15 20

More info and screens

2

2. Health

2.1 Basic Checks

TESS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TESS has been increased compared to 1 year ago.
TESS has more shares outstanding than it did 5 years ago.
TESS has a worse debt/assets ratio than last year.
TESS Yearly Shares OutstandingTESS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
TESS Yearly Total Debt VS Total AssetsTESS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

TESS has an Altman-Z score of 2.66. This is not the best score and indicates that TESS is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.66, TESS is in the better half of the industry, outperforming 71.67% of the companies in the same industry.
A Debt/Equity ratio of 0.96 indicates that TESS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.96, TESS is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Altman-Z 2.66
ROIC/WACCN/A
WACC8.49%
TESS Yearly LT Debt VS Equity VS FCFTESS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.98 indicates that TESS should not have too much problems paying its short term obligations.
The Current ratio of TESS (1.98) is comparable to the rest of the industry.
A Quick Ratio of 1.09 indicates that TESS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.09, TESS is doing worse than 60.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.98
Quick Ratio 1.09
TESS Yearly Current Assets VS Current LiabilitesTESS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

TESS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.14%.
The Revenue has grown by 8.19% in the past year. This is quite good.
TESS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.87% yearly.
EPS 1Y (TTM)-35.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-408.33%
Revenue 1Y (TTM)8.19%
Revenue growth 3Y-5.77%
Revenue growth 5Y-4.87%
Sales Q2Q%2.57%

3.2 Future

Based on estimates for the next years, TESS will show a very strong growth in Earnings Per Share. The EPS will grow by 48.46% on average per year.
Based on estimates for the next years, TESS will show a small growth in Revenue. The Revenue will grow by 4.16% on average per year.
EPS Next Y120.4%
EPS Next 2Y48.46%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y4.16%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TESS Yearly Revenue VS EstimatesTESS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
TESS Yearly EPS VS EstimatesTESS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1 -1 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TESS. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 88.14, TESS can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TESS indicates a slightly more expensive valuation: TESS is more expensive than 60.00% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.63. TESS is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 88.14
TESS Price Earnings VS Forward Price EarningsTESS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

TESS's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 97.29
TESS Per share dataTESS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

TESS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TESS's earnings are expected to grow with 48.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.46%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TESS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TESSCO Technologies Inc

NASDAQ:TESS (7/14/2023, 8:02:40 PM)

After market: 8.99 0 (0%)

8.99

+0.01 (+0.11%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryCommunications Equipment
Earnings (Last)05-26 2023-05-26/amc
Earnings (Next)07-25 2023-07-25/amc
Inst Owners0.51%
Inst Owner Change0%
Ins Owners37.15%
Ins Owner Change0%
Market Cap83.30M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)55.51%
Min EPS beat(2)-19.61%
Max EPS beat(2)130.64%
EPS beat(4)3
Avg EPS beat(4)89.07%
Min EPS beat(4)-19.61%
Max EPS beat(4)190.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.87%
Min Revenue beat(2)-12.05%
Max Revenue beat(2)-1.69%
Revenue beat(4)2
Avg Revenue beat(4)-1.78%
Min Revenue beat(4)-12.05%
Max Revenue beat(4)4.39%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0.14%
Revenue NQ rev (3m)0.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 88.14
P/S 0.18
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 2.57
EV/EBITDA 97.29
EPS(TTM)-0.5
EYN/A
EPS(NY)0.1
Fwd EY1.13%
FCF(TTM)-2.99
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS48.76
BVpS7.89
TBVpS3.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.16%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.85%
GM growth 5Y-0.55%
F-Score3
Asset Turnover1.94
Health
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Debt/EBITDA 44.76
Cap/Depr 406.07%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.98
Quick Ratio 1.09
Altman-Z 2.66
F-Score3
WACC8.49%
ROIC/WACCN/A
Cap/Depr(3y)368.35%
Cap/Depr(5y)283.51%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-408.33%
EPS Next Y120.4%
EPS Next 2Y48.46%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.19%
Revenue growth 3Y-5.77%
Revenue growth 5Y-4.87%
Sales Q2Q%2.57%
Revenue Next Year0%
Revenue Next 2Y4.16%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year591.36%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-130.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-379.16%
OCF growth 3YN/A
OCF growth 5YN/A